Hear from heart valve treatment experts as they discuss the pivot of TAVR to the low risk U.S. patient population in this roundtable video discussion. Learn about the low risk indication and what it means for TAVR patients with symptomatic severe aortic stenosis in this series of short videos.
Steven Yakubov, M.D.
Kendra J. Grubb, M.D.
Kevin Stiver, M.D.
Toby Rogers, M.D.
The video series is divided into chapters for ease of viewing. You can watch the chapters in any order, although they appear in the sequence below. Click on a link below or scroll down the page to view a specific chapter.
Welcome to the Spotlight on TAVR video series: Pivoting to the Low Risk Population. Videos focus on the expansion and movement into the low risk patient population, with insight from an expert panel of heart valve treatment experts.
Details of low risk TAVR study and data. Impact on patients, including those previously routed to surgery. Includes insight on safety of TAVR at one-year mark, and how cardiology community has been engaged with data.
Experts weigh in on how to reach patients who are not diagnosed with symptomatic severe aortic stenosis, and discussions around the importance of identifying and referring patients in a timely manner.
Considerations and factors for lifetime management of TAVR valves. Results from trials and discussions on surgical options. Includes example of how low risk patients are evaluated.
TAVR and the Low Risk Patient Population Video Series | Key Topics around Low Risk Patients
How to counsel patients regarding pacemakers after a TAVR procedure if needed, with insights into the approach.
TAVR and the Low Risk Patient Population Video Series | Pacemaker Considerations
Discussion includes hemodynamics, gradients, and small-annulus patients. Rationale around why heart team approach is preferred.
TAVR and the Low Risk Patient Population Video Series|Gradients and Selecting the Correct Valve Size
Discussion on the use of cerebral embolic protection for management of stroke, and the benefits of conscious sedation.
Where are we going with low risk? What are the big hurdles for TAVR and surgical valves? What are the future possibilities?